首页> 外文OA文献 >Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer

【2h】

Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer

机译：欧洲委员会关于乳腺癌倡议的建议，以指导使用激素受体阳性，Her-2阴性，淋巴结阴性或多达3个淋巴结阳性侵入性乳腺癌的患者使用佐剂化疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
P.Giorgi Rossi; A. Lebeau; C. Canelo-Aybar; M.C. Posso Rivera; D.Rigau Comas; C. Quinn; P.Alonso Coello; H. McGarrigle; S. Warman; M. Broeders; S. Duffy; M.W. Langendam; A. Gräwingholt; M. Follmann; Z. Saz-Parkinson; H. Schünemann;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative [J] . Paolo Giorgi Rossi, Annette Lebeau, Carlos Canelo-Aybar, British Journal of Cancer . 2021,第9期

机译：欧洲委员会乳腺癌倡议的建议，用于制定使用早期乳腺癌，激素受体阳性的辅助化疗使用辅助化疗，HER-2负
2. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy [J] . Young-Joon Kang, Wonshik Han, Soojin Park, Breast cancer research and treatment. . 2017,第2期

机译：在Neoadjuvant化疗后，乳腺癌淋巴结活检导向乳腺癌患者中的乳腺癌患者的决定
3. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103) [J] . Miller Kathy D., ONeill Anne, Gradishar William, Journal of Clinical Oncology . 2018,第25期

机译：淋巴结阳性和高风险淋巴结阴性乳腺癌（E5103）患者辅助化疗的双盲期III试验辅助化疗及没有Bevacizumab（E5103）
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. Evaluation of pathologic parameters and published nomograms in predicting non-sentinel lymph node metastases in female breast cancer patients with positive sentinel lymph nodes. [D] . Murch, Lisa Elaine. 2007

机译：在前哨淋巴结阳性的女性乳腺癌患者中预测非前哨淋巴结转移的病理参数和公布的列线图评估。
6. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103) [O] . Kathy D. Miller, Anne O’Neill, William Gradishar, -1

机译：淋巴结阳性和高风险淋巴结阴性乳腺癌患者接受或不接受贝伐单抗辅助化疗的双盲III期试验（E5103）
7. Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative [O] . Paolo Giorgi Rossi, Annette Lebeau, Carlos Canelo-Aybar, 2021

机译：欧洲委员会乳腺癌倡议的建议，用于多尾试验，以指导利用辅助化疗的早期乳腺癌患者，激素受体阳性，HER-2负

Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer

著录项

相似文献

相关主题

期刊订阅